Add Yahoo as a preferred source to see more of our stories on Google. Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com (MAXIMUM ...
Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher Jeffrey Agar and a team of scientists came up with a technique that improves ...
Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...
A Lawrence Livermore National Laboratory (LLNL)-led team of scientists and computational engineers using one of the largest electronic health record datasets ever assembled for ALS has identified ...
Why are so many amyotrophic lateral sclerosis (ALS) drug trials are failing? And what makes a new candidate drug called COYA 302, an investigational therapy for ALS, different? COYA 302 is a ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) has ...
Acting US Food and Drug Administration (FDA) Commissioner Ned Sharpless on Thursday announced that the agency would finalize guidance on developing treatments for amyotrophic lateral sclerosis (ALS) ...
Scientists have learned more about the effects of an experimental amyotrophic lateral sclerosis (ALS) drug candidate that failed its promise. This study has shown that the drug was able to enter the ...
The US Food and Drug Administration (FDA) on Monday finalized guidance to assist in the clinical development of treatments for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results